Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Summary

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.

The Respiratory Syncytial Virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from US$36.88m in 2018 to US$1.48bn by 2028 across the five growth markets (*5GM - Australia, India, Japan, South Korea and urban China) in the Asia-Pacific (APAC) region. The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.

The level of unmet need in the Respiratory Syncytial Virus (RSV) marketplace is high in India and urban China, where there are currently no prophylactic or therapeutic options. The launch of the first Respiratory Syncytial Virus (RSV) products in 2023 in urban China and 2024 in India is expected to be a strong driver of growth for the 5GM over the forecast period, especially considering the large potential patient populations in these markets.

Research reveals that the current standard of care and only available product for Respiratory Syncytial Virus (RSV), AstraZeneca/AbbVie’s Synagis (palivizumab), is likely to be displaced during the forecast period. Synagis is currently the only licensed product in Australia, South Korea and Japan for prevention of Respiratory Syncytial Virus (RSV) infections in young children, but its high price and restrictive label have narrowed its clinical applications to only the highest-risk infants.

In addition, the requirement for five monthly injections of Synagis is a substantial barrier to full patient compliance. Sales of Synagis are expected to drop substantially after the launch of AstraZeneca/Sanofi’s pipeline candidate mAb MEDI8897 in 2024, which is projected to reach US$629m in annual revenue by 2028. MEDI8897 will also provide the first prophylactic mAb option for patients in India and urban China.

It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections. However, the global impact of new products in reducing the overall Respiratory Syncytial Virus (RSV) burden will depend on the cost-effectiveness of these drugs, as well as how vaccines are eventually integrated into national immunization policies throughout the 5GM - Australia, India, Japan, South Korea and urban China.

The latest research report “Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028” helps in answering the following question with regards to Respiratory Syncytial Virus (RSV) and its therapeutic market in Asia Pacific.

How will the Respiratory Syncytial Virus (RSV) therapeutic market landscape in the 5GM (India, urban China, Australia, South Korea and Japan) change from 2018-2028?

What are the most promising late-stage pipeline drugs for RSV?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another and against existing treatment options?
What are the remaining unmet needs in Respiratory Syncytial Virus (RSV) treatment management?
What drivers and barriers will affect Respiratory Syncytial Virus (RSV) therapeutics sales in the 5GM - Australia, India, Japan, South Korea and urban China over the forecast period?

Scope

Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline RSV market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting RSV therapeutics sales in the 5GM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global RSV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Asia-Pacific RSV market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Respiratory Syncytial Virus: Executive Summary

1.1 Strong Growth Projected for the RSV Market from 2018 to 2028
1.2 Both Large and Small Developers Are Focused on the Untapped RSV Therapeutics Market
1.3 The Market for Cost-Effective Prophylaxis Is Highly Competitive
1.4 Despite Projected Entrance of Novel Products, Opportunities Remain for Current and Future Players
1.5 Future RSV Management Strategies Will Include Multiple Products
1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used and Not Used
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for RSV Hospitalized Population (2018-2028)
4.5.1 Number of Hospitalized Adults with Positive RSV Test
4.5.2 Number of Children Hospitalized for Confirmed RSV
4.6 Epidemiological Forecast for RSV Prophylactic Population (2018-2028)
4.6.1 Number of Preterm Births by Gestational Age
4.6.2 Preterm Infants with CLD
4.6.3 Number of Live Births with Hemodynamically Significant Heart Disease
4.6.4 Diagnosed Prevalent Cases of DMD
4.6.5 Number of Diagnosed Prevalent Cases of SMA
4.6.6 Number of Third Trimester Pregnant Women
4.6.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions
4.7 Discussion
4.7.1 Epidemiological Forecast Insight
4.7.2 Limitations of Analysis
4.7.3 Strengths of Analysis

5 Current Treatment Options

5.1 Overview

6 Unmet Needs and Opportunity Assessment in Asia-Pacific

6.1 Overview
6.2 Improved Cost-Effective Passive Prophylaxis
6.3 Prophylactic Vaccines
6.4 Effective Antivirals

7 R&D Strategies in Asia-Pacific

7.1 Overview
7.1.1 Leveraging Novel Vaccine Technologies and Strategies
7.1.2 Development of Prophylactic Antibodies with Improved Dosing and Efficacy
7.1.3 Development of RSV Antiviral Therapeutics with Diverse Mechanisms of Action
7.2 Clinical Trials Design
7.2.1 Clinical Trials Design of Pipeline Prophylactics for Maternal Immunization
7.2.2 Clinical Trials Design of Pipeline Prophylactics for Pediatric Immunization
7.2.3 Clinical Trials Design of Pipeline Prophylactics for Adult Immunization
7.2.4 Demonstration of Efficacy for Fusion Inhibitor Antivirals
7.2.5 Demonstration of Efficacy for Replication Inhibitor Antivirals

8 Pipeline Assessment in Asia-Pacific

8.1 Overview
8.2 Innovative Early-Stage Approaches
8.3 Other Drugs in Development

9 Pipeline Valuation Analysis10 Appendix

List of Tables

Table 1: Respiratory Syncytial Virus: Key Metrics in the 5GM
Table 2: Risk Factors for Severe RSV
Table 3: Treatment Guidelines for RSV
Table 4: Leading Treatments for RSV, 2019
Table 5: Clinical Trial Designs for RSV Vaccines for Maternal Immunization
Table 6: Clinical Trial Designs for RSV Prophylactics for Pediatric Patients
Table 7: Clinical Trial Designs for RSV Prophylactics for Adult Patients
Table 8: Clinical Trial Designs for RSV Fusion Inhibitor Therapeutics
Table 9: Clinical Trial Designs for RSV Replication Inhibitor Therapeutics
Table 10: Innovative Early-Stage Approaches for RSV, 2019
Table 11: Drugs in Development for RSV, 2019
Table 12: Clinical Benchmark of Key Pipeline Therapeutics
Table 13: Clinical Benchmark of Key Pipeline Prophylactics - RSV mAbs
Table 14: Clinical Benchmark of Key Pipeline Prophylactics - RSV Vaccines
Table 15: Commercial Benchmark of Key Pipeline Therapeutics
Table 16: Commercial Benchmark of Key Pipeline Prophylactics - RSV mAbs
Table 17: Commercial Benchmark of Key Pipeline Prophylactics - RSV Vaccines
Table 18: Key Events Impacting Sales for RSV, 2018-2028
Table 19: RSV Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Historical and Projected Launch Dates for RSV
Table 21: Key Historical and Projected Patent Expiry Dates for RSV
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 5GM Sales Forecast by Country for RSV in 2018 and 2028
Figure 2: Competitive Assessment of Pipeline Therapeutics Benchmarked Against Janssen’s Experimental Antiviral JNJ-53718678
Figure 3: Competitive Assessment of the Marketed and Pipeline Prophylactics Benchmarked Against AstraZeneca’s Synagis
Figure 4: Structure of the Human RSV Virion
Figure 5: Replication Cycle of RSV
Figure 6: 5GM, Children, Boys and Girls, 0-2 Years Old, Confirmed RSV Hospitalizations, N, 2008 and 2018
Figure 7: 5GM, Rate of Preterm Births (per 1,000 Live Births), 2008-2018
Figure 8: 5GM, Percentage of Adults Living in Long-Term Care, Ages =55 Years, 2008-2018
Figure 9: 5GM, Sources Used to Forecast the Number of Adults Hospitalized Who Test Positive for RSV, 2018-2028
Figure 10: 5GM, Sources Used to Forecast the Number of Children Hospitalized with Confirmed RSV
Figure 11: 5GM, Sources Used to Forecast the Number of Preterm Births
Figure 12: 5GM, Sources Used to Forecast the Number of Preterm Births with CLD, 2018-2028
Figure 13: 5GM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
Figure 14: 5GM, Sources Used to Forecast Diagnosed Prevalent Cases of DMD
Figure 15: 5GM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 16: 5GM, Sources Used to Forecast the Number of Third Trimester Pregnancies
Figure 17: 5GM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
Figure 18: 5GM, Number of Hospitalized Adults with Positive RSV Test, Ages =60 Years, Men and Women, 2018
Figure 19: 5GM, Number of Children Hospitalized for Confirmed RSV, Ages 0-2 Years, Boys and Girls, 2018
Figure 20: 5GM, Number of Preterm Births by Gestational Age, N, 2018
Figure 21: 5GM, Number of Preterm Infants with CLD, N, 2018-2028
Figure 22: 5GM, Number of Live Births with Hemodynamically Significant Heart Disease, 2018-2028
Figure 23: 5GM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2018-2028
Figure 24: 5GM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2018-2028
Figure 25: 5GM, Number of Third Trimester Pregnant Women, N, 2018-2028
Figure 26: 5GM, Number of Adults Living in Long-Term Care Institutions, Ages =55 Years, N, 2018-2028
Figure 27: Unmet Needs and Opportunities in RSV
Figure 28: Overview of the Development Pipeline in RSV
Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that the Author Expects to Be Licensed for RSV in the 5GM During the Forecast Period
Figure 30: Competitive Assessment of Pipeline Antivirals
Figure 31: Competitive Assessment of the Pipeline Prophylactics Benchmarked Against the Current SOC, Synagis
Figure 32: 5GM Sales Forecast by Country for RSV in 2018 and 2028
Figure 33: Global Sales Forecast by Product for RSV in 2028
Figure 34: Therapeutic Sales Forecast by Product for RSV in India from 2018 to 2028
Figure 35: Prophylactic Sales Forecast by Class for RSV in India from 2018 to 2028
Figure 36: Therapeutic Sales Forecast by Product for RSV in Urban China from 2018 to 2028
Figure 37: Prophylactic Sales Forecast by Class for RSV in Urban China from 2018 to 2028
Figure 38: Therapeutic Sales Forecast by Product for RSV in Australia from 2018 to 2028
Figure 39: Prophylactic Sales Forecast by Class for RSV in Australia from 2018 to 2028
Figure 40: Therapeutic Sales Forecast by Product for RSV in South Korea from 2018 to 2028
Figure 41: Prophylactic Sales Forecast by Class for RSV in South Korea from 2018 to 2028
Figure 42: Therapeutic Sales Forecast by Product for RSV in Japan from 2018 to 2028
Figure 43: Prophylactic Sales Forecast by Class for RSV in Japan from 2018 to 2028

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Ark Biosciences
AstraZeneca
Bavarian Nordic
Enanta Pharmaceuticals
GlaxoSmithKline
Janssen
Merck & Co.
Novavax
Pfizer
Pulmocide
ReViral

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€8936EUR$8,995USD£7,430GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€17872EUR$17,990USD£14,860GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€26808EUR$26,985USD£22,290GBP

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

Respiratory Syncytial Virus (RSV) Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Respiratory syncytial virus (RSV) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

VAC 18193 Market Size, Forecast, and Emerging Insight - 2032